Literature DB >> 15105100

Variety of beta-lactamases produced by amoxicillin-clavulanate-resistant Escherichia coli isolated in the northeastern United States.

Keith S Kaye1, Howard S Gold, Mitchell J Schwaber, Lata Venkataraman, Youlin Qi, Paola C De Girolami, Matthew H Samore, Greg Anderson, J Kamile Rasheed, Fred C Tenover.   

Abstract

This study analyzed the enzymatic basis and molecular epidemiology of amoxicillin-clavulanate-resistant Escherichia coli isolated by the microbiology laboratory of a United States tertiary care hospital. From October 1998 to December 1999, all E. coli isolates were screened for ampicillin-sulbactam resistance. Of 283 isolates that tested resistant to ampicillin-sulbactam, 69 unique patient isolates were also resistant to amoxicillin-clavulanate by disk diffusion testing (zone diameter </= 13 mm). These amoxicillin-clavulanate-resistant E. coli isolates underwent agar dilution testing, pulsed-field gel electrophoresis, PCR analysis, and isoelectric focusing. The mean age of study patients was 52 years; 78% were female. Among the isolates, 12 were nosocomial (rate of amoxicillin-clavulanate resistance = 4.7%) and 57 were community acquired (rate of amoxicillin-clavulanate resistance = 2.8%). No predominant strain was identified. By agar dilution testing, 67 isolates were nonsusceptible (39 resistant and 28 intermediate) to amoxicillin-clavulanate and 37 were piperacillin-tazobactam resistant but only 8 were ceftazidime resistant (ceftazidime MIC >/= 32 micro g/ml). Two isolates were susceptible to amoxicillin-clavulanic acid by agar dilution, although they were resistant by disk diffusion testing. The distribution of beta-lactamases was as follows: the TEM type alone was found in 52 isolates, the AmpC type was found in 4 isolates (2 identified as containing CMY-2), the TEM type and CMY-2 were found in 2 isolates, and the OXA type was found in 1 isolate. Also, there was one isolate with the TEM type and the SHV type and one with the TEM type and a second, unidentified enzyme. Among the isolates with TEM-type enzymes, two extended-spectrum beta-lactamase-producing isolates were identified but two isolates with inhibitor-resistant TEM (IRT) enzymes (one with TEM-34 [IRT-6] and the other with a novel enzyme [tentatively assigned the designation TEM-122]) were more interesting.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15105100      PMCID: PMC400555          DOI: 10.1128/AAC.48.5.1520-1525.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  29 in total

Review 1.  Inhibitor-resistant TEM beta-lactamases: phenotypic, genetic and biochemical characteristics.

Authors:  E B Chaïbi; D Sirot; G Paul; R Labia
Journal:  J Antimicrob Chemother       Date:  1999-04       Impact factor: 5.790

2.  Prevalence of resistance to beta-lactam antibiotics in Escherichia coli isolated from blood from 1969-1991.

Authors:  K Shannon; A King; I Phillips
Journal:  J Antimicrob Chemother       Date:  1992-11       Impact factor: 5.790

3.  Evolution of extended-spectrum beta-lactam resistance (SHV-8) in a strain of Escherichia coli during multiple episodes of bacteremia.

Authors:  J K Rasheed; C Jay; B Metchock; F Berkowitz; L Weigel; J Crellin; C Steward; B Hill; A A Medeiros; F C Tenover
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

Review 4.  Magnitude and prevention of nosocomial infections in the intensive care unit.

Authors:  S K Fridkin; S F Welbel; R A Weinstein
Journal:  Infect Dis Clin North Am       Date:  1997-06       Impact factor: 5.982

Review 5.  A functional classification scheme for beta-lactamases and its correlation with molecular structure.

Authors:  K Bush; G A Jacoby; A A Medeiros
Journal:  Antimicrob Agents Chemother       Date:  1995-06       Impact factor: 5.191

6.  Emergence of clinical isolates of Escherichia coli producing TEM-1 derivatives or an OXA-1 beta-lactamase conferring resistance to beta-lactamase inhibitors.

Authors:  X Y Zhou; F Bordon; D Sirot; M D Kitzis; L Gutmann
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

7.  Risk factors for recovery of ampicillin-sulbactam-resistant Escherichia coli in hospitalized patients.

Authors:  K S Kaye; A D Harris; H Gold; Y Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

8.  Properties of IRT-14 (TEM-45), a newly characterized mutant of TEM-type beta-lactamases.

Authors:  M M Caniça; M Barthélémy; L Gilly; R Labia; R Krishnamoorthy; G Paul
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

Review 9.  beta-Lactamases in laboratory and clinical resistance.

Authors:  D M Livermore
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

10.  Frequency of inhibitor-resistant TEM beta-lactamases in Escherichia coli isolates from urinary tract infections in France.

Authors:  C Henquell; D Sirot; C Chanal; C De Champs; P Chatron; B Lafeuille; P Texier; J Sirot; R Cluzel
Journal:  J Antimicrob Chemother       Date:  1994-11       Impact factor: 5.790

View more
  21 in total

1.  Endocarditis caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: emergence of resistance to ciprofloxacin and piperacillin-tazobactam during treatment despite initial susceptibility.

Authors:  Oren Zimhony; Inna Chmelnitsky; Rita Bardenstein; Sorel Goland; Orly Hammer Muntz; Shiri Navon Venezia; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

2.  Evaluation of four commercially available extended-spectrum beta-lactamase phenotypic confirmation tests.

Authors:  Andrea J Linscott; William J Brown
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

3.  High levels of antimicrobial coresistance among extended-spectrum-beta-lactamase-producing Enterobacteriaceae.

Authors:  Mitchell J Schwaber; Shiri Navon-Venezia; David Schwartz; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

4.  Multiplex PCR scheme for variant plasmid mediated class C β-lactamase typing.

Authors:  Le Van Chuong; Virapong Prachayasittikul; Chartchalerm Isarankura Na Ayudhya; Ratana Lawung
Journal:  J Clin Lab Anal       Date:  2017-07-18       Impact factor: 2.352

Review 5.  Epidemiology of β-Lactamase-Producing Pathogens.

Authors:  Karen Bush; Patricia A Bradford
Journal:  Clin Microbiol Rev       Date:  2020-02-26       Impact factor: 26.132

Review 6.  Current challenges in antimicrobial chemotherapy: focus on ß-lactamase inhibition.

Authors:  Carine Bebrone; Patricia Lassaux; Lionel Vercheval; Jean-Sébastien Sohier; Adrien Jehaes; Eric Sauvage; Moreno Galleni
Journal:  Drugs       Date:  2010-04-16       Impact factor: 9.546

7.  Detection of resistance to beta-lactamase inhibitors in strains with CTX-M beta-lactamases: a multicenter external proficiency study using a well-defined collection of Escherichia coli strains.

Authors:  Aida Ripoll; Juan-Carlos Galán; Cristina Rodríguez; Nuria Tormo; Concepción Gimeno; Fernando Baquero; Luis Martínez-Martínez; Rafael Cantón
Journal:  J Clin Microbiol       Date:  2013-10-23       Impact factor: 5.948

8.  Integrated detection of extended-spectrum-beta-lactam resistance by DNA microarray-based genotyping of TEM, SHV, and CTX-M genes.

Authors:  Dirk M Leinberger; Verena Grimm; Maya Rubtsova; Jan Weile; Klaus Schröppel; Thomas A Wichelhaus; Cornelius Knabbe; Rolf D Schmid; Till T Bachmann
Journal:  J Clin Microbiol       Date:  2009-12-09       Impact factor: 5.948

9.  Pharmacodynamic Evaluation of the Potential Clinical Utility of Fosfomycin and Meropenem in Combination Therapy against KPC-2-Producing Klebsiella pneumoniae.

Authors:  James Albiero; Sherwin K B Sy; Josmar Mazucheli; Silvana Martins Caparroz-Assef; Bruno Buranello Costa; Janio Leal Borges Alves; Ana Cristina Gales; Maria Cristina Bronharo Tognim
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

10.  Population-based laboratory surveillance for AmpC beta-lactamase-producing Escherichia coli, Calgary.

Authors:  Johann D D Pitout; Daniel B Gregson; Deirdre L Church; Kevin B Laupland
Journal:  Emerg Infect Dis       Date:  2007-03       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.